T. Rowe Price Associates
HRMY icon

T. Rowe Price Associates’s Harmony Biosciences HRMY Stock Holding History

T. Rowe Price Associates’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Buy
58,865
+11,151
+23% +$352K ﹤0.01% 1966
2026
Q1 		$1.34M Buy
47,714
+6,255
+15% +$205K ﹤0.01% 1999
2025
Q4 		$1.55M Buy
41,459
+5,011
+14% +$165K ﹤0.01% 1874
2025
Q3 		$1M Buy
36,448
+1,616
+5% +$55.7K ﹤0.01% 2066
2025
Q2 		$1.1M Buy
34,832
+4,993
+17% +$161K ﹤0.01% 1948
2025
Q1 		$991K Buy
29,839
+10,051
+51% +$360K ﹤0.01% 1963
2024
Q4 		$681K Buy
19,788
+4,911
+33% +$169K ﹤0.01% 2148
2024
Q3 		$596K Buy
14,877
+185
+1% +$6.5K ﹤0.01% 2182
2024
Q2 		$444K Buy
14,692
+473
+3% +$14.2K ﹤0.01% 2235
2024
Q1 		$478K Buy
14,219
+1,201
+9% +$38.5K ﹤0.01% 2230
2023
Q4 		$421K Buy
13,018
+620
+5% +$17.3K ﹤0.01% 2252
2023
Q3 		$407K Buy
12,398
+717
+6% +$24.9K ﹤0.01% 2211
2023
Q2 		$412K Buy
11,681
+1,628
+16% +$56.2K ﹤0.01% 2222
2023
Q1 		$329K Buy
10,053
+454
+5% +$20.7K ﹤0.01% 2299
2022
Q4 		$529K Buy
9,599
+357
+4% +$19.6K ﹤0.01% 2104
2022
Q3 		$410K Buy
9,242
+1,740
+23% +$84.9K ﹤0.01% 2228
2022
Q2 		$366K Buy
7,502
+437
+6% +$19.7K ﹤0.01% 2358
2022
Q1 		$344K Buy
7,065
+500
+8% +$20.4K ﹤0.01% 2492
2021
Q4 		$280K Buy
+6,565
New +$262K ﹤0.01% 2613
2020
Q4 		– Sell
-209,361
Closed -$7.1M – 2696
2020
Q3 		$7.1M Buy
+209,361
New +$7.63M ﹤0.01% 1363

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's HRMY Position: Q2 2026 in Review

T. Rowe Price Associates increased its Harmony Biosciences (HRMY) stake by 23% in Q2 2026, buying an estimated $352K and bringing the position to 58,865 shares worth $2.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1966.

T. Rowe Price Associates first reported a position in HRMY in Q3 2020 and has held it in 20 quarters since. The position peaked at $7.1M in Q3 2020. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • T. Rowe Price Associates held 58,865 shares of Harmony Biosciences worth $2.14M as of Q2 2026.
  • T. Rowe Price Associates bought 11,151 Harmony Biosciences shares in Q2 2026, an estimated $352K.
  • Harmony Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1966 holding.
  • T. Rowe Price Associates first reported a position in Harmony Biosciences in Q3 2020 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Harmony Biosciences position peaked at $7.1M in Q3 2020.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.